Bombora and ZoomInfo Intent both do a real job well: surfacing which companies are showing an unusual spike in research activity around a topic, at genuine scale, across thousands of publisher sites. That is useful directional evidence for a lot of B2B categories. It is a weaker fit for life science specifically, where the events that actually predict a purchase decision, a trial phase transition, an FDA milestone, a funding close, are not web-content topics at all, they are documented public events.
What each intent tool is actually good at
Quote-only annual contracts, commonly reported starting around $30,000 a year and scaling into six figures
The original B2B intent data provider, built from a co-op network of thousands of publisher websites tracking content consumption across 12,000-plus research topics, refreshed on a regular cadence.
Best for: Teams that want the broadest, most established topic-surge dataset as a standalone layer on top of an existing contact database.
Bundled into ZoomInfo's higher-tier packages or sold as an add-on; buyers commonly report a mid five-figure contract before it becomes meaningful
Real-time streaming intent alerts alongside AI-recommended topics correlated with a team's own historical closed-won deals, packaged into the same platform as ZoomInfo's contact and company data.
Best for: Teams already running ZoomInfo for contact data who want topic-level intent in the same platform rather than a second contract.
Free tier, then usage-based plans scaling from roughly the low hundreds to several hundred dollars a month
Can wire multiple signal providers, including Bombora, into one workflow and apply custom logic on top, useful for teams that want to combine several signal sources without a single-vendor lock-in.
Best for: Technical RevOps teams that want to build a custom, multi-source signal workflow and are prepared to maintain it as sources and edge cases change.
Why generic intent misses the life science signal
Generic intent tools miss the life science signal because they only track anonymized, aggregated content-consumption behavior, page visits, article reads, and search activity on the publisher sites in their co-op networks, rolled up to a company level, not the documented events that actually predict a life science purchase decision. A surge in that behavior around a relevant topic is a genuine, if indirect, signal in a lot of industries. But in life science, the strongest evidence of readiness rarely shows up as a topic-research spike at all. See buying signals for biotech and pharma sales for the full breakdown of the categories that actually matter: capital events, clinical and regulatory milestones, hiring into a specific function, and conference activity. None of these are reliably captured by a general content-intent topic, because they are documented events at a named company, not a pattern of anonymized web behavior.
The stitching burden vs. one life science-native signal engine
A team trying to get life science-relevant signal coverage out of generic intent tools usually ends up layering Bombora or ZoomInfo Intent on top of a contact database, then building a separate manual process, someone checking clinical trial registries, FDA databases, and press releases by hand, to catch the events that actually move a life science buying process. That is real, ongoing analyst time, and it still needs to be cross-referenced against fit before it is useful, since a strong signal at a company outside your ICP is not a lead.
Arcova unifies that narrower, specific motion end to end: it watches clinical trial registries, FDA databases, funding and grant announcements, hiring activity, and conference exhibitor and speaker lists for accounts that already pass your fit criteria, and rolls the raw events up into the readiness categories covered in timing outreach with readiness signals. That is the one motion Arcova owns end to end: finding and interpreting the life science signal, not generic web-intent tracking at Bombora or ZoomInfo's scale, which are different, broader products solving a different problem.
When generic intent data is still worth having
Generic intent data is still worth having when your team sells a horizontal product into life science as one vertical among several, or your buyers genuinely do show up in generic B2B research topics like cloud infrastructure, security, or HR software. In those cases, Bombora or ZoomInfo Intent's broad topic coverage is a real advantage a life science-only signal engine is not trying to replicate. The two are not mutually exclusive, and teams selling a mixed book often want both: general topic intent for the horizontal parts of the business, and life science-specific signal tracking for the parts that are not.
For a fast, definitional reference to every signal type mentioned here, see the GTM signals glossary for life science sales, and for the data layer these signals get layered onto, see the best sales intelligence tools for life science.